6:36 PM
 | 
Jun 05, 2008
 |  BC Extra  |  Top Story

Ipsen unveils trio of deals

Ipsen (Euronext:IPN) announced three deals that it said will increase its North American presence, including an agreement to acquire its U.S. partner Tercica (NASDAQ:TRCA) for $441 million. The Tercica deal will give Ipsen back U.S. and Canadian rights to Somatuline Depot, which it licensed to Tercica in 2006. The extended-release injectable formulation of somatostatin analog lanreotide is approved in the U.S. and EU to treat acromegaly and in the EU to treat neuroendocrine tumors, where it is marketed by Ipsen as Somatuline Autogel....

Read the full 435 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >